An observational study in Breast Cancer and Breast Cancer and Pregnancy, sponsored by Jules Bordet Institute. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Jules Bordet Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is one of 3 that started in 2026, is one of 4 observational ones, and was the 42nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:
Jules Bordet Institute · Sites in Belgium
Ages 18+ · Women only
Jules Bordet Institute · Sites in Belgium
Ages 18–70 · Women only
Jules Bordet Institute · Sites in Belgium
Ages 18+ · Women only
Jules Bordet Institute · Sites in Belgium, Germany, Iceland and 7 more countries
Ages 18+
Jules Bordet Institute
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,200 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 49 across the 38 interventional studies, 1,200 across the 4 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
1 of the studies in Breast Neoplasms by Jules Bordet Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06150898Jules Bordet InstituteKetorolac and Pregabalin Effects on breaSt Cancer (KePreSt) | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study aims to refine the understanding of the prognostic impact of pregnancy after breast cancer in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA
This retrospective, multicenter, observational study aims to evaluate the prognostic impact of pregnancy after breast cancer diagnosis in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA1/2, including TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, and RAD51D.
Although pregnancy after breast cancer has been shown to be safe in the overall population of young breast cancer survivors and in carriers of BRCA1/2 pathogenic variants, evidence remains limited for patients with pathogenic variants in other breast cancer susceptibility genes. This knowledge gap represents a relevant unmet need in oncofertility counseling and survivorship care.
The study will include patients diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2025. The primary objectives are to assess the prognostic impact of pregnancy after breast cancer diagnosis and to evaluate the cumulative incidence of pregnancy in this population. Secondary objectives include the assessment of pregnancy, fetal, and obstetrical outcomes, the safety of assisted reproductive technology procedures, patterns of care including risk-reducing surgeries, survival outcomes according to clinicopathologic and genetic subgroups, and the occurrence of second primary malignancies.
Data will be collected retrospectively from participating centers within the Beyond BRCA BCY Collaboration.
Young women diagnosed at age 40 years or younger with stage I-III invasive breast cancer between January 2000 and December 2025 and harboring a germline pathogenic variant in a breast cancer susceptibility gene other than BRCA1/2, including TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, and RAD51D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women with one or more pregnancies any time after breast cancer diagnosis
Women with no subsequent pregnancies after breast cancer diagnosis
Cumulative Incidence of Pregnancy After Breast Cancer Diagnosis
Time frame: Up to 20 years from breast cancer diagnosis
Invasive Disease-Free Survival (iDFS)
Time frame: Up to 20 years from breast cancer diagnosis
No study locations are listed for this record.
Plan to share: Undecided — De-identified individual participant data may be shared upon reasonable request, subject to submission of a formal research proposal to the study Principal Investigators and review and approval by the study leadership. Any data sharing will be subject to applicable ethics approvals, data transfer agreements, local institutional requirements, and data protection regulations.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.